CyberHeart Takes Non-invasive Approach To AF Ablation

CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. Current clinical trials are examining the use of CyberHeart not only for atrial fibrillation (AF) treatment, but also for ventricular tachycardia, for which a US pivotal trial is scheduled for early 2017.

Catheter-based atrial fibrillation (AF) ablation procedures have spared countless patients from open-heart surgery, and companies continue to improve on that technology. ([A#MT103609]) But an entirely non-invasive ablation option could soon be available. CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. The treatment requires no anesthesia, and patients go home the same day.

Patrick Maguire, MD, PhD, a cardiac surgeon who once performed open AF ablation or maze procedures, is president and CEO...

More from Startups & SMEs

More from Business